CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012

[January 11, 2013]

Research and Markets: Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/vxnpvt/fluad_seasonal) has announced the addition of GlobalData's new report "Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis" to their offering.

Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccies with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Fluad is a trivalent, inactivated influenza vaccine that contains MF59 adjuvant, an oil-in-water emulsion containing squalene, polysorbate 80, and sorbitan trioleate. The virus strains present in the vaccine are grown in chicken eggs, harvested via centrifugation, inactivated with formaldehyde, and the surface antigens are purified via further centrifugation. The vaccine is indicated for immunization against seasonal influenza via intramuscular injection, and the MF59 adjuvant boosts the immune response of the recipient. Fluad was designed to improve the efficacy of influenza vaccines in elderly patients, who have waning immune systems. Fluad is marketed by Novartis in numerous European and Asian counties, including France, German, Spain, and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Appendix

For more information visit http://www.researchandmarkets.com/research/vxnpvt/fluad_seasonal

Source (News - Alert): GlobalData


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter